$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Parathyroid hormone (PTH) is secreted by the parathyroid glands. It is a major modulator of the calcium balance, maintains phosphate metabolism, and participates in bone turnover1,2. Hypoparathyroidism (HypoPT) manifests as a decreased secretion or functional loss of PTH. It is a rare endocrine disorder, with a prevalence of approximately 9-37 per 100,000 person-years3,4,5. HypoPT is characterized by decreased serum PTH and calcium levels accompanied by increased serum phosphorus6,7. HypoPT is classified based on its cause: acquired hypoparathyroidism (AHypoPT) or idiopathic hypoparathyroidism (IHypoPT)8. AHypoPT is more commonly encountered in clinical practice; about 75% of AHypoPT cases are caused by resection or accidental injury of the parathyroid glands during thyroid surgery or other head and neck surgeries. Other causes include radiotherapy and chemotherapy for head and neck tumors and drug toxicity1,8. Upgraded diagnostic methods and an increase in screening for thyroid gland-associated diseases have increased the number of thyroid gland surgical operations. This has led to a corresponding increase in the related parathyroid gland complications9,10.
Easily established animal models with stable characteristics are needed to better investigate AHypoPT and verify the therapeutic effectiveness of novel treatments. Parathyroidectomy (PTX) performed on rats and mice has been reported in previous studies6,11; however, due to the extremely small size of the parathyroid glands and the variability in their anatomical distribution, the success rate is relatively low in practice. Thus, thyro-parathyroidectomy (TPTX) (i.e., the total removal of the thyroid and parathyroid glands) is usually performed to ensure the resection of the parathyroid glands12. However, the resulting low thyroxine levels may complicate studies with this animal model13. HypoPT models established by other methods, such as drug stimulation and gene editing, cannot properly represent the most common AHypoPT pathogenesis. Our group previously used knockout mouse models to label the parathyroid glands and allow the removal of the parathyroid glands without damaging the thyroid glands and surrounding anatomical structures14,15. However, this method utilizes transgenic mouse models, which require a longer development time due to the mating and breeding requirements.
Therefore, we aimed to establish an easily generated model of AHypoPT. This study describes a rat model for PTX using carbon nanoparticle labeling. A carbon nanoparticle suspension of 50 mg/mL, which is commonly used in thyroid surgery, evenly distributes in the thyroid glands after local injection16. The thyroid glands turn black, but the parathyroid glands are left unstained17, thus clearly distinguishing the parathyroid glands from the thyroid glands and allowing the PTX to be performed without affecting the thyroid glands. This method is suitable for rats of different ages. The injection of the carbon nanoparticle suspension is safe and has a negligible effect on thyroid function18. The carbon nanoparticle-labeled PTX rat model generated in this study showed significant hypocalcemia and hyperphosphatemia phenotypes during the 4 week observation period. Thus, this AHypoPT model is easy to establish and has a reproducible phenotype.